Jefferies Financial Group Inc. Invests $3.58 Million in Edwards Lifesciences Corporation $EW

Posted by Geri Gentry on Aug 29th, 2026

Jefferies Financial Group Inc. acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 39,620 shares of the medical research company’s stock, valued at approximately $3,584,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of Edwards Lifesciences during the second quarter worth about $5,318,092,000. Bank of New York Mellon Corp bought a new position in Edwards Lifesciences in the 2nd quarter worth about $1,274,082,000. Norges Bank bought a new position in Edwards Lifesciences in the 4th quarter worth about $803,686,000. Bank of America Corp DE acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $605,397,000. Finally, Deutsche Bank AG bought a new stake in shares of Edwards Lifesciences during the second quarter valued at approximately $516,552,000. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, VP Annette Bruls sold 2,644 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the sale, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the transaction, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. This represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,501 shares of company stock valued at $408,213 over the last 90 days. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Up 0.3%

EW opened at $90.19 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The company has a market capitalization of $51.93 billion, a PE ratio of 51.83, a P/E/G ratio of 2.36 and a beta of 0.85. The stock’s fifty day moving average is $89.54 and its 200-day moving average is $85.03. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29.

Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. During the same period in the previous year, the business earned $0.67 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on EW. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price target for the company from $87.00 to $101.00 in a report on Friday, July 24th. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Evercore reiterated an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research report on Monday, July 6th. Finally, TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Read Our Latest Research Report on EW

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.